Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude pour évaluer les traitements préventifs de la toxicité orale liée au talquetamab (Talisman)

24 septembre 2026 mis à jour par: Janssen Research & Development, LLC

Une étude de phase 2, ouverte et randomisée pour évaluer les interventions prophylactiques sur la toxicité orale liée au talquetamab

The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste changes and to better characterize the signs or symptoms of ramantamig-related taste changes.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

210

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Brasília, Brésil, 70390-140
        • Recrutement
        • IDOR - Regional Brasilia
      • Caxias do Sul, Brésil, 95070 560
        • Recrutement
        • Fundacao Universidade de Caxias do Sul
      • Curitiba, Brésil, 81520-060
        • Recrutement
        • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
      • Salvador, Brésil, 41253-190
        • Recrutement
        • IDOR - Regional Bahia
      • São Paulo, Brésil, 04537 081
        • Recrutement
        • Clinica Medica Sao Germano LTDA
      • São Paulo, Brésil, 01401 002
        • Recrutement
        • IDOR - Regional Sao Paulo
      • Seoul, Corée du Sud, 03080
        • Recrutement
        • Seoul National University Hospital
      • Seoul, Corée du Sud, 06591
        • Recrutement
        • The Catholic University of Korea Seoul St Mary s Hospital
      • Seoul, Corée du Sud, 135-230
        • Recrutement
        • Samsung Medical Center
      • Badalona, Espagne, 08916
        • Recrutement
        • Hosp. Univ. Germans Trias I Pujol
      • Barcelona, Espagne, 08036
        • Recrutement
        • Hosp Clinic de Barcelona
      • El Palmar, Espagne, 30120
        • Recrutement
        • Hosp. Univ. Virgen de La Arrixaca
      • Jerez de la Frontera, Espagne, 11407
        • Recrutement
        • Hosp. de Jerez de La Frontera
      • Madrid, Espagne, 28034
        • Recrutement
        • Hosp. Univ. Ramon Y Cajal
      • Madrid, Espagne, 28041
        • Recrutement
        • Hosp. Univ. 12 de Octubre
      • Pozuelo de Alarcón, Espagne, 28223
        • Recrutement
        • Hosp. Quiron Madrid Pozuelo
      • Salamanca, Espagne, 37007
        • Recrutement
        • Hosp Clinico Univ de Salamanca
      • Amsterdam, Pays-Bas, 1081 HV
        • Recrutement
        • VUMC Amsterdam
      • Dordrecht, Pays-Bas, 3318 AT
        • Recrutement
        • Albert Schweitzer Ziekenhuis
      • Rotterdam, Pays-Bas, 3015 CN
        • Recrutement
        • Erasmus MC
      • San Juan, Porto Rico, 00918
        • Recrutement
        • Hospital Espanol Auxilio Mutuo Auxilio Mutuo Cancer Center
      • Belfast, Royaume-Uni, BT9 7AB
        • Recrutement
        • Belfast City Hospital
      • Colchester, Royaume-Uni, CO4 5JL
        • Recrutement
        • Colchester Hospital University NHS
      • Eastbourne, Royaume-Uni, BN21 2UD
        • Recrutement
        • Eastbourne District General Hospital
      • Liverpool, Royaume-Uni, L7 8YA
        • Recrutement
        • The Clatterbridge Cancer Centre
      • London, Royaume-Uni, W12 0HS
        • Recrutement
        • Hammersmith Hospital
      • London, Royaume-Uni, NW1 2BU
        • Recrutement
        • University College London Hospitals
      • Manchester, Royaume-Uni, M20 4BX
        • Recrutement
        • The Christie NHS Foundation Trust Christie Hospital
      • Newcastle upon Tyne, Royaume-Uni, NE7 7DN
        • Complété
        • Newcastle Freeman Hospital
    • California
      • San Francisco, California, États-Unis, 94143
        • Recrutement
        • University of California San Francisco
    • Colorado
      • Denver, Colorado, États-Unis, 80218
        • Recrutement
        • Colorado Blood Cancer Institute
    • Connecticut
      • New Haven, Connecticut, États-Unis, 06510
        • Recrutement
        • Yale University School Of Medicine
    • New York
      • New York, New York, États-Unis, 10029
        • Recrutement
        • Icahn School of Medicine at Mt. Sinai
      • Rochester, New York, États-Unis, 14642
        • Recrutement
        • University of Rochester Medical Center
    • North Carolina
      • Durham, North Carolina, États-Unis, 27705
        • Recrutement
        • Duke University Medical Center
    • Ohio
      • Cleveland, Ohio, États-Unis, 44106
        • Recrutement
        • University Hospitals Cleveland Medical Center
    • Virginia
      • Richmond, Virginia, États-Unis, 23298
        • Recrutement
        • Virginia Commonwealth University - Massey Cancer Center
    • Washington
      • Seattle, Washington, États-Unis, 98109
        • Recrutement
        • University of Washington

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Multiple myeloma (MM) according to IMWG diagnostic criteria
  • Were triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb)
  • Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen
  • Have an Eastern Cooperative Oncology Group-performance status (ECOG-PS) of 0 or 1 at screening. Participants with ECOG-PS 2 or 3 are eligible for the study if the ECOG-PS score is related to stable physical limitations (e.g., wheelchair-bound due to prior spinal cord injury) and not related to multiple myeloma or associated therapy
  • Be willing and able to adhere to the lifestyle restrictions specified in the protocol

Exclusion Criteria:

  • Contraindications or life-threatening known allergies, hypersensitivity, or intolerance to any study drug or its excipients
  • Stroke, transient ischemic attack, or seizure within 6 months prior to screening
  • Any of the following within 6 months prior to the first dose of study treatment: severe or unstable angina, myocardial infarction; major thromboembolytic event (e.g., pulmonary embolism, cerebrovascular accident), clinically significant ventricular arrythmia or heart failure New York Heart Association functional classification Class III or IV. Uncomplicated deep vein thrombosis is not considered exclusionary
  • Major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment
  • A WETT score indicating severe dysgeusia at screening and confirmed prior to randomization. Also unresolved/severe dysgeusia referred by the participant or a finding in the physical examination/oral cavity inspection. Some examples include leukoplakia, prior mouth cancers, extensive dental caries, severe periodontitis, active oral infections, candidiasis, parotic gland removal, or radiotherapy with resultant xerostomia

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Cohort A: Talquetamab

Participants with relapsed or refractory multiple myeloma (RRMM) who are triple-class exposed (previously exposed to at least 1 proteasome inhibitor [PI], 1 immunomodulatory drug(s) [IMiD]), and an anti-CD38 monoclonal antibody [mAb]) will be treated with talquetamab subcutaneously until disease progression, death, unacceptable toxicity, withdrawal of consent, discontinuation of talquetamab, or end of study, whichever occurs first.

Talquetamab will be administered subcutaneously.

Autres noms:
  • CD3xGPRC5D
Expérimental: Cohort B: Prophylaxis A and Talquetamab

Participants with RRMM who are triple-class exposed (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive prophylaxis A along with talquetamab therapy. Participants will start the assigned prophylaxis 7 days before starting talquetamab treatment. After step-up dosing of talquetamab therapy, participants will be treated with talquetamab with prophylaxes for up to 12 months during prophylaxis treatment phase (if there are clinical benefits prophylaxis treatment can continue beyond 12 months, at the treating physician's discretion, after consultation with sponsor). The Talquetamab treatment phase will continue from Cycle 1 Day 1 (C1D1) until disease progression, death, unacceptable toxicity, withdrawal of consent, discontinuation of talquetamab, or end of study, whichever occurs first.

Talquetamab will be administered subcutaneously.

Autres noms:
  • CD3xGPRC5D

Prophylaxis A will be administered orally.

Expérimental: Cohort C: Prophylaxis B and Talquetamab

Participants with RRMM who are triple-class exposed (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive prophylaxis B along with talquetamab therapy. Participants will start the assigned prophylaxis 7 days before starting talquetamab treatment. After step-up dosing of talquetamab therapy, participants will be treated with talquetamab with prophylaxes for up to 12 months during prophylaxis treatment phase (if there are clinical benefits prophylaxis treatment can continue beyond 12 months, at the treating physician's discretion, after consultation with sponsor). The Talquetamab treatment phase will continue from C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent, discontinuation of talquetamab, or end of study, whichever occurs first.

Talquetamab will be administered subcutaneously.

Autres noms:
  • CD3xGPRC5D

Prophylaxis B will be administered orally.

Expérimental: Cohort D: Prophylaxis C and Talquetamab

Participants with RRMM who are triple-class exposed (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive prophylaxis C along with talquetamab therapy. Participants will start the assigned prophylaxis 7 days before starting talquetamab treatment. After step-up dosing of talquetamab therapy, participants will be treated with talquetamab with prophylaxes for up to 12 months during prophylaxis treatment phase (if there are clinical benefits prophylaxis treatment can continue beyond 12 months, at the treating physician's discretion, after consultation with sponsor). The Talquetamab treatment phase will continue from C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent, discontinuation of talquetamab, or end of study, whichever occurs first.

Talquetamab will be administered subcutaneously.

Autres noms:
  • CD3xGPRC5D

Prophylaxis C will be administered orally.

Expérimental: Cohort E: Prophylaxis D and Talquetamab

Participants with RRMM who are triple-class exposed (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive prophylaxis D along with talquetamab therapy. Participants will start the assigned prophylaxis 1 day before starting talquetamab treatment. After step-up dosing of talquetamab therapy, participants will be treated with talquetamab with prophylaxes for up to 12 months during prophylaxis treatment phase (if there are clinical benefits prophylaxis treatment can continue beyond 12 months, at the treating physician's discretion, after consultation with sponsor). The Talquetamab treatment phase will continue from C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent, discontinuation of talquetamab, or end of study, whichever occurs first.

Talquetamab will be administered subcutaneously.

Autres noms:
  • CD3xGPRC5D

Prophylaxis D will be administered topically.

Expérimental: Cohort F: Ramantamig

Participants with RRMM who are triple-class exposed (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive single step-up dose of ramantamig subcutaneously followed by the treatment dose until disease progression, death, unacceptable toxicity, withdrawal of consent, discontinuation of ramantamig, or end of study, whichever occurs first.

Ramantamig will be administered subcutaneously.

Autres noms:
  • BCMAxGPRC5DxCD3

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of Participants With Occurrence of Dysgeusia as Assessed by the Total Waterless Empirical Taste Test (WETT) Testing Score During the Prophylaxis Treatment Phase
Délai: Up to 12 months

Dysgeusia is defined as total WETT score of 25th percentile or below according to the Normative WETT-SA53 percentile table. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53. The score will be graded by a qualified site staff into a normative percentile score using a provided chart.

Up to 12 months
Percentage of Participants With Occurrence of Severe Dysgeusia During the Prophylaxis Treatment Phase
Délai: Up to 12 months

Severe Dysgeusia is defined as a total WETT score of 10th percentile or below according to the normative WETT-SA53 percentile table. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53. The score will be graded by a qualified site staff into a normative percentile score using a provided chart.

Up to 12 months
Time to the First Onset of Severe Dysgeusia During the Prophylaxis Treatment Phase
Délai: Up to 12 months

Time to the first onset of severe dysgeusia is defined as time from the first dose date of talquetamab to the first onset date of severe dysgeusia according to the total WETT score. For participants without severe dysgeusia, time to the first onset will be censored. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53. The score will be graded by a qualified site staff into a normative percentile score using a provided chart.

Up to 12 months
Percentage of Participants Who Report Resolution/Improvement of Dysgeusia During the Prophylaxis Treatment Phase
Délai: End of Month 3

Resolution/improvement is defined as 2 potential scenarios: 1) A dysgeusia downgraded to dysgeusia-free, that is (i.e.,) total WETT score of 25th percentile or below at visits prior to the end of month 3 becomes total WETT score above 25th percentile at the end of month 3. 2) Severe dysgeusia downgraded to non-severe dysgeusia, i.e., total WETT score of 10th percentile or below prior to the end of month 3 becomes total WETT score above 10th percentile at the end of month 3. Taste assessment will be performed using taste strips (WETT). Four concentrations will be used for each taste quality: sweet, sour, salty, bitter, & umami. Each test kit contains 53 taste strips; numbered (1 through 53). Participants will use each strip sequentially and record flavor on score card provided. Test will result in maximum (i.e., best) total score of 53. Score will be graded by qualified staff into normative percentile score using provided chart.

End of Month 3
Percentage of Participants Who Report Resolution/Improvement of Dysgeusia During the Prophylaxis Treatment Phase
Délai: End of Month 7

Resolution/improvement is defined as 2 potential scenarios: 1) A dysgeusia downgraded to dysgeusia-free, that is (i.e.,) total WETT score of 25th percentile or below at visits prior to the end of month 7 becomes total WETT score above 25th percentile at the end of month 7. 2) Severe dysgeusia downgraded to non-severe dysgeusia, i.e., total WETT score of 10th percentile or below prior to the end of month 7 becomes total WETT score above 10th percentile at the end of month 7. Taste assessment will be performed using taste strips (WETT). Four concentrations will be used for each taste quality: sweet, sour, salty, bitter, & umami. Each test kit contains 53 taste strips; numbered (1 through 53). Participants will use each strip sequentially and record flavor on score card provided. Test will result in maximum (i.e., best) total score of 53. Score will be graded by qualified staff into normative percentile score using provided chart.

End of Month 7

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change From Baseline in WETT Testing Score Over Time
Délai: Baseline up to 36 months

Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53.

Baseline up to 36 months
Percentage of Time with Dysgeusia During the Prophylaxis Treatment Phase
Délai: Up to 12 months

Time with dysgeusia is defined as the accumulative days a participant had dysgeusia according to the total WETT score divided by the total days of talquetamab exposure. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53. The score will be graded by a qualified site staff into a normative percentile score using a provided chart.

Up to 12 months
Percentage of Participants with Treatment-Emergent Oral Toxicities (Dysgeusia, Oral Mucositis, Dysphagia, and Xerostomia) During the Prophylaxis Treatment Phase
Délai: Up to 12 months

Oral toxicity including dysgeusia, oral mucositis, dysphagia, and xerostomia will be graded (including Grade 0 for dysgeusia) based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 5.0. Severity has 5 grades based on CTCAE criteria: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening consequences; and Grade 5: Death.

Up to 12 months
Percentage of Participants with Treatment-Emergent Oral Toxicities (Dysgeusia, Oral Mucositis, Dysphagia, and Xerostomia) During the Study
Délai: Up to 30 days after the last dose of study treatment (that is, approximately up to 36 months)

Oral toxicity including dysgeusia, oral mucositis, dysphagia, and xerostomia will be graded (including Grade 0 for dysgeusia) based on NCI-CTCAE, Version 5.0. Severity has 5 grades based on CTCAE criteria: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening consequences; and Grade 5: Death.

Up to 30 days after the last dose of study treatment (that is, approximately up to 36 months)
Time to the First Onset of Treatment-Emergent Oral Toxicities (Dysgeusia, Oral Mucositis, Dysphagia, and Xerostomia)
Délai: Up to 36 months

Time to the first onset of treatment-emergent dysgeusia, oral mucositis, dysphagia, or xerostomia, will be reported.

Up to 36 months
Duration of Treatment-emergent Oral Toxicities (Dysgeusia, Oral Mucositis, Dysphagia, and Xerostomia)
Délai: Up to 36 months

Duration of treatment-emergent oral toxicities including dysgeusia, oral mucositis, dysphagia, and xerostomia will be reported in this outcome measure.

Up to 36 months
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 items (EORTC-QLQ-C30) Domains Scores Over Time
Délai: From Baseline, up to 12 months (Cohorts A to E); up to 24 months (for Cohort F)

The EORTC-QLQ-C30 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 5 single symptom items (dyspnea, insomnia, appetite loss, constipation, and diarrhea) and a single impact item (financial difficulties). The recall period is 7 days, and responses are reported using verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high health related quality of life (HRQoL), but a high score for a symptom scale/item represents a high level of symptomatology/problems.

From Baseline, up to 12 months (Cohorts A to E); up to 24 months (for Cohort F)
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Oral Health (EORTC-QLQ-OH15) Domains Scores Over Time
Délai: From Baseline, up to 12 months (Cohorts A to E); up to 24 months (for Cohort F)

The EORTC module QLQ-OH15 is a 15-item, well-accepted, and validated assessment tool focusing on oral problems and quality of life. The recall period for symptoms is 7 days and response options include 'not at all', "a little', 'quite a bit', and 'very much'. All of the items' measures range in score from 0 to 100. A high score for the symptom items represents a high level of symptomatology or problems.

From Baseline, up to 12 months (Cohorts A to E); up to 24 months (for Cohort F)
Percentage of Participants Reporting Oral Symptoms Using the Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Délai: Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)

PRO-CTCAE is a patient-reported item custom survey used to evaluate symptomatic treatment-emergent adverse events in participants on cancer clinical trials. The PRO-CTCAE custom survey consists of 18 items. Responses are provided on a 5-point Likert scale that ranges from 0 to 4. The recall period for symptoms is 7 days. Higher scores indicating greater severity/impact.

Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)
Percentage of Participants Reporting Oral Symptoms Using the Short Xerostomia Inventory (SXI) Score
Délai: Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)

SXI is a validated questionnaire that explores how the participant experiences dry mouth (xerostomia) with 5 questions extracted from the original XI. Respondents are asked to choose 1 of 5 responses ("1-Never; 2-Hardly ever; 3-Occasionally; 4-Fairly often; and 5-Very often") to specific statements referring to the preceding 4 weeks. Each individual's responses are scored and summed to give a single XI score. Higher scores represent more severe symptoms.

Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)
Percentage of Participants Reporting Oral Symptoms Using the Epstein Taste Survey (ETS)
Délai: Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)

The Epstein Taste Survey (ETS) consists of 17 items PRO instrument, specific to taste and smell changes. The ETS was developed for use in participants with head and neck cancer. This instrument will be used to measure treatment-related symptoms associated with talquetamab.

Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)
Percentage of Participants Reporting Oral Symptoms Using the Scale of Subjective Total Taste Acuity (STTA)
Délai: Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)

The STTA is a tool to assess the overall acuity of taste based on a 4-point scale, where 0 reflects no change and 4 represents almost complete loss of taste function. Higher score indicating severity.

Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)
Change from Baseline in Body Weight Over Time
Délai: From Baseline up to 36 months

Change from baseline in body weight will be reported.

From Baseline up to 36 months
Change from Baseline in Body Mass Index (BMI) Over Time
Délai: From Baseline up to 36 months

Change from baseline in BMI will be reported.

From Baseline up to 36 months
Percentage of Participants With Dose Reductions, Interruptions, and Discontinuations For Talquetamab and Ramantamig
Délai: Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)

Percentage of participants with dose reductions, dose interruptions, and dose discontinuations will be reported.

Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)
Change from Baseline in Smell Identification Test Score
Délai: Baseline (Day 1 Cycle 1), Day 1 Cycle 2 (each cycle duration=28-days)

Smell identification testing will be performed using 4 booklets each containing 10 labels that will release a distinctive scent when scraped with a pencil. Participants will choose the appropriate scent from the associated options. The minimum possible score is a 0 and the maximum is a 40. A higher score indicates better smell/outcome.

Baseline (Day 1 Cycle 1), Day 1 Cycle 2 (each cycle duration=28-days)
Percentage of Participants With Overall Response Rate
Délai: Up to 36 months

Overall response rate is defined as the participants with a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria.

Up to 36 months
Percentage of Participants With Complete Response (CR) or Better Response
Délai: Up to 36 months

CR or better response is defined as the participants who achieve a CR or better response according to the IMWG criteria.

Up to 36 months
Percentage of Participants With Very Good Partial Response (VGPR) or Better Response
Délai: Up to 36 months

VGPR or better response is defined as the percentage of participants who achieve a VGPR or better response according to the IMWG criteria.

Up to 36 months
Duration of Response (DOR)
Délai: Up to 36 months

Duration of response is defined as time from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria, or death due to any reason, whichever occurs first.

Up to 36 months
Time to Response (TTR)
Délai: Up to 36 months

Time to response is defined as the time between date of first dose of talquetamab or ramantamig and the first efficacy evaluation at which the participant has met all criteria for PR or better.

Up to 36 months
Progression-free Survival (PFS)
Délai: Up to 36 months

PFS is defined as the time from the date of first dose of talquetamab or ramantamig to the date of first documented disease progression, as defined in the IMWG criteria, or death due to any cause, whichever occurs first.

Up to 36 months
Number of Participants with Treatment-emergent Adverse Event (TEAEs)
Délai: Up to 36 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Any AE occurring at or after the initial administration of study treatment through the day of last dose plus 30 days, or if beyond 30 days from last dose but is study treatment-related, is considered to be treatment-emergent.

Up to 36 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

26 août 2024

Achèvement primaire (Estimé)

30 mai 2030

Achèvement de l'étude (Estimé)

30 mai 2030

Dates d'inscription aux études

Première soumission

8 juillet 2024

Première soumission répondant aux critères de contrôle qualité

8 juillet 2024

Première publication (Réel)

15 juillet 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

25 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

24 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner